MRTX - Mirati Therapeutics Q3 2022 Earnings Preview
- Mirati Therapeutics ( NASDAQ: MRTX ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, after market close.
- The consensus EPS Estimate is -$3.48 and the consensus Revenue Estimate is $1.37M (-98.1% Y/Y).
- Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward.
For further details see:
Mirati Therapeutics Q3 2022 Earnings Preview